Effect of early and late compliance on the effectiveness of acamprosate in the treatment of alcohol dependence

Journal of Substance Abuse Treatment

Volumn 39, Issue 3, 2010, Pages 218-226

  Koeter, Maarten W J ^a,b   van den Brink, Wim ^a,b   Lehert, Philippe ^c,d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b AMSTERDAM INSTITUTE FOR ADDICTION RESEARCH   (Netherlands)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d Louvain Academy   (Belgium)

Author keywords

Acamprosate; Alcohol dependence; Compliance; IPD meta analysis

Indexed keywords

ACAMPROSATE; PLACEBO;

ADULT; AGE; ALCOHOL ABSTINENCE; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MOTIVATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ALCOHOL DETERRENTS; ALCOHOLISM; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MOTIVATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REGRESSION ANALYSIS; TAURINE; TEMPERANCE; TIME FACTORS;

EID: 77956413963     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2010.06.002     Document Type: Article

References (38)

1. Anton R.F., et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: A randomized controlled trial. JAMA 2006, 295:2003-2017.
2. Baros A.M., Latham P.K., Moak D.H., et al. What role does measuring medication compliance play in evaluating the efficacy of naltrexone?. Alcoholism, Clinical and Experimental Research 2007, 31:596-603.
3. Besson J., Aeby F., Kasas A., et al. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: A controlled study. Alcoholism, Clinical and Experimental Research 1998, 22:573-579.
4. Borg, S., unpublished data 1994.
5. Bouza C., Angeles M., Munoz A., et al. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction 2004, 99:811-828.
6. Chalmers T.C., Smith H., Blackburn B., et al. A method for assessing the quality of a randomized control trial. Controlled Clinical Trials 1981, 2:31-49.
7. Chick J., Howlett H., Morgan M.Y., et al. United Kingdom Multicentre Acamprosate Study (UKMAS): A 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 2000, 35:176-187.
8. Cramer J.C. Effect of partial compliance on cardiovascular medication effectiveness. Heart 2002, 88:203-206.
9. DerSimonian R., Laird N. Meta analysis in clinical trials. Controlled Clinical Trials 1986, 7:177-188.
10. Duncan A.J. Quality control and industrial statistics 1986, 229-241. Irwin, Homewood, IL. 5th ed.
11. Edwards D. On model prespecification in confirmatory randomized studies. Statistics in Medicine 1999, 18:771-785.
12. Evangelista L.S. Compliance: A concept analysis. Nursing forum 1999, 34:5-11.
13. Feinn R., Tennen H., Cramer J., et al. Measurement and prediction of medication compliance in problem drinkers. Alcoholism, Clinical and Experimental Research 2003, 27:1286-1292.
14. Geerlings P.J., Ansoms C., van den Brink W. Acamprosate and prevention of relapse in alcoholics. Results of a randomized, placebo-controlled, double-blind study in out-patient alcoholics in The Netherlands, Belgium and Luxembourg. European Addiction Research 1997, 3:129-137.
15. Gual A., Lehert P. Acamprosate during and after acute alcohol withdrawal: A double-blind placebo-controlled study in Spain. Alcohol Alohol 2001, 36:413-418.
16. Higgins J.T., Whitehead A., Turner R., et al. Meta analysis of continuous outcome data from individual patients. Statistics in Medicine 2001, 20:2219-2241.
17. Kranzler H.R. Acamprosate efficacy in alcohol-dependent patients: Summary of results from three pivotal trials. American Journal on Addictions 2008, 17:70-76.
18. Kyngas H., Duffy M.E., Kroll T. Conceptual analysis of compliance. Journal of Clinical Nursing 2000, 9:5-12.
19. Ladewig D., Knecht T., Leher P., et al. Acamprosate-A stabilizing factor in long-term withdrawal of alcoholic patients. Therapeutische Umschau. Revue therapeutique 1993, 50:182-188.
20. MacKinnon D.P. Introduction to statistical mediation analysis 2008, Erlbaum, Mahwah, NJ.
21. MacKinnon D.P., Lockwood C.M., Williams J. Confidence limits for the indirect effect: Distribution of the product and resampling methods. Multivariate Behavioral Research 2004, 39:99-128.
22. Mann K., Lehert P., Morgan M.Y. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: Results of a meta-analysis. Alcoholism, Clinical and Experimental Research 2004, 28:51-63.
23. McDonough K.P. Alcohol dependence and pharmacologic treatment. Introduction. American Journal Of Health-System Pharmacy 2007, 64(Suppl3):53-54.
24. McLellan A.T., Lewis D.C., O'Brein C.P., et al. Drug dependence, a chronic medical illness. Implications for treatment, insurance, and outcome evaluation. JAMA 2000, 284:1689-1695.
25. Miller W.R., Wilbourne P.L. Mesa Grande: A methodological analysis of clinical trials of treatments for alcohol use disorders. Addiction 2002, 97:265-277.
26. Pelc I., Le Bon O., Verbanck P., et al. Calcium acetyl homotaurinate for maintaining abstinence in weaned alcoholic patients; A placebo controlled double-blind multi-centre study. Novel pharmacological interventions for alcoholism 1992, 348-352. Springer Verlag, New York. C. Naranjo, E. Sellers (Eds.).
27. Pelc I., Verbanck P., Le Bon O., et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. The British Journal of Psychiatry 1997, 171:73-77.
28. Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 1997, 92:1537-1546.
29. Preacher K.J., Hayes A.F. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behavior Research Methods 2008, 40:879-891.
30. Rousseaux J.P., Hers D., Ferauge M. Does acamprosate influence alcohol consumption of weaned alcoholics?. Journal de pharmacie de Belgique 1996, 51:65-68.
31. Simmonds M.C., Higgins J.P., Steward L.A., et al. Meta analysis of individual patient data for randomized trials: A review of methods used in practice. Clinical Trials 2005, 2005(2):209-217.
32. Smith T.D., Williamson P.R., Marson A.G. Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes. Statistics in Medicine 2005, 24:1307-1319.
33. Spanagel R., Kiefer F. Drugs for relapse prevention of alcoholism: Ten years of progress. Trends Pharmacol Sci 2008, 29:109-115.
34. Tempesta E., Janiri L., Bignamini A., et al. Acamprosate and relapse prevention in the treatment of alcohol dependence: A placebo-controlled study. Alcohol Alcohol 2000, 35:202-209.
35. Volpicelli J.R., Rhines K.C., Volpicelli L.A., et al. Naltrexone and alcohol dependence. Role of subject compliance. Archives of General Psychiatry 1997, 54:737-742.
36. Weiss R.D. Adherence to pharmacotherapy in patients with alcohol and opiod dependence. Addiction 2004, 99:1382-1392.
37. Wilde M.I., Wagstaff A.J. Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 1997, 53:1038-1053.
38. Yuen K.H., Peh K.K., et al. Comparative bioavailability study of a generic naltrexone tablet preparation. Drug Development and Industrial Pharmacy 1999, 25:353-356.